Is Mindray Medical profitable in 2026?

Yes but declining. FY2025 net profit fell about 30.28 percent year over year to CNY 8.14 to 8.45 billion on revenue of CNY 33.28 billion, itself down 9.4 percent, reported March 31, 2026. Q4 2025 net profit collapsed to roughly CNY 566 million, prompting analyst questions about accounting adjustments.

Why is Mindray's stock down in 2026?

China's healthcare anti-corruption crackdown drove a 23 percent drop in domestic revenue to CNY 15.6 billion in FY2025, and the stock has fallen from an all-time high of CNY 503.51 to roughly CNY 141 to 186 through H1 2026, per GuruFocus data as of July 24, 2026.

Who owns Mindray Medical?

Mindray has no controlling parent. It listed on the NYSE in September 2006, went private in a $1.9 billion buyout completed March 2016, and re-listed on the Shenzhen Stock Exchange as SZSE:300760 in October 2018. Founders Li Xiting and Xu Hang remain major shareholders alongside institutional investors.

Could AI replace Mindray's business?

Unlikely soon. Mindray's moat is regulatory clearance and hospital procurement incumbency for physical hardware, which pure AI software cannot replicate quickly. Mindray is instead embedding AI into its own devices, such as the Resona I9T ultrasound with AutoEF and eStrain features, reviewed July 15, 2026.

Who is Mindray's biggest competitor?

GE HealthCare, Philips, Siemens Healthineers, and Roche Diagnostics are Mindray's closest rivals, each roughly 4 to 6 times larger by revenue, with Siemens Healthineers near $27 billion versus Mindray's approximately $4.8 billion FY2025 revenue, but they are structurally blocked from China's price-sensitive hospital tenders.

Will US tariffs hurt Mindray Medical?

New Section 301 tariffs of 10 to 12.5 percent on roughly 60 countries took effect July 24, 2026, after the Supreme Court struck down earlier IEEPA-based tariffs in February 2026, directly taxing Chinese-manufactured devices as Mindray expands US operations via its Mahwah, New Jersey warehouse.

Biotech tools companies · China

Mindray Medical International

mindray.com ↗

Chinese maker of patient monitors, ultrasound, IVD, and lab instruments sold worldwide.

Defensible for now

Assessed 24 July 2026 · Evidence as of 24 July 2026

Real protection, with named pressure against it.

On the recordSince 24 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: H1 2026 earnings report, watched for China revenue stabilization and Q4 accounting anomaly resolution

The call

A global device maker whose near term wobble comes from a China procurement crackdown at home, not from AI or Western rivals taking its customers.

Mindray makes ultrasound machines, patient monitors, and lab equipment sold mostly in China and emerging markets. It is hard to replace because hospitals get locked into its products through service contracts and supplies (40% of revenue comes back as recurring orders), and Mindray builds these devices cheaply enough that Western rivals like GE HealthCare and Philips cannot compete on price without hurting their own premium business. The company faces three immediate clouds: China's government is cutting hospital spending to fight corruption (revenue dropped 23% in 2025), there is a profit mystery in Q4 2025 that may need accounting fixes, and new US tariffs starting July 2026 could raise costs on the international sales that now drive growth.

Why

AI pressure: AI-enabled diagnostic and imaging software makers. AI software layers could commoditize hardware differences over time, but Mindray is also folding AI features into its own monitors and IVD lines. Could AI do the core job? Unlikely.

Bigger players: GE HealthCare, Philips, Siemens Healthineers, Roche Diagnostics. These rivals sell competing monitors, imaging, and IVD gear globally, but Mindray's China revenue drop traces to a domestic procurement crackdown, not share loss to them. Could a giant copy it? No, they are blocked.

What protects it. Regulatory clearances, a huge installed hospital base, ~40% recurring consumables revenue, and lower manufacturing costs than Western rivals in China and emerging markets.

What would change this call

H1 2026 earnings (~August 2026) show China domestic revenue trend. Reveals whether the procurement crackdown is easing or still driving customer loss.
Resolution of the ~CNY 566M Q4 2025 profit anomaly. Shows whether financial reporting concerns were a one-off or signal deeper issues.
US Section 301 tariff level after July 2026 (stays at 10-12.5% or escalates). Indicates whether international expansion, now over 50% of revenue, faces new cost pressure.

Key numbers

H1 2025 revenue CNY16.74B, down 18.45% y/y (2025-08-27)
Recurring revenue ~40% of H1 2025 revenue (2026-01-22)
International revenue grew at ~15% CAGR, now 50% of total (2026-01-22)

Named risks

China anti-corruption crackdown drove 23% domestic revenue drop in FY2025, procurement freeze may persist. Severity: high
New Section 301 US tariffs of 10 to 12.5% effective July 24, 2026 threaten Chinese-made device exports to the US. Severity: medium
Unresolved Q4 2025 profit anomaly (~CNY 566 million) raises risk of accounting restatement. Severity: medium
Stock down from CNY 503.51 all-time high to CNY 141 to 186 range signals sustained investor concern through H1 2026. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
GE HealthCare	contesting	GE HealthCare ~$20.6B revenue vs Mindray's ~$4.8B FY2025, but blocked from China tender pricing
Philips	contesting	Philips ~$20.5B revenue dwarfs Mindray, yet lacks China hospital procurement incumbency, 2026
Siemens Healthineers	contesting	Siemens Healthineers ~$27B revenue, cannot match Mindray's China cost structure, 2026
Roche Diagnostics	contesting	Roche Diagnostics ~$17.3B revenue vs Mindray's ~4% global IVD share, per Jan 2026 disclosure

Questions people ask

Is Mindray Medical profitable in 2026?: Yes but declining. FY2025 net profit fell about 30.28 percent year over year to CNY 8.14 to 8.45 billion on revenue of CNY 33.28 billion, itself down 9.4 percent, reported March 31, 2026. Q4 2025 net profit collapsed to roughly CNY 566 million, prompting analyst questions about accounting adjustments.
Why is Mindray's stock down in 2026?: China's healthcare anti-corruption crackdown drove a 23 percent drop in domestic revenue to CNY 15.6 billion in FY2025, and the stock has fallen from an all-time high of CNY 503.51 to roughly CNY 141 to 186 through H1 2026, per GuruFocus data as of July 24, 2026.
Who owns Mindray Medical?: Mindray has no controlling parent. It listed on the NYSE in September 2006, went private in a $1.9 billion buyout completed March 2016, and re-listed on the Shenzhen Stock Exchange as SZSE:300760 in October 2018. Founders Li Xiting and Xu Hang remain major shareholders alongside institutional investors.
Could AI replace Mindray's business?: Unlikely soon. Mindray's moat is regulatory clearance and hospital procurement incumbency for physical hardware, which pure AI software cannot replicate quickly. Mindray is instead embedding AI into its own devices, such as the Resona I9T ultrasound with AutoEF and eStrain features, reviewed July 15, 2026.
Who is Mindray's biggest competitor?: GE HealthCare, Philips, Siemens Healthineers, and Roche Diagnostics are Mindray's closest rivals, each roughly 4 to 6 times larger by revenue, with Siemens Healthineers near $27 billion versus Mindray's approximately $4.8 billion FY2025 revenue, but they are structurally blocked from China's price-sensitive hospital tenders.
Will US tariffs hurt Mindray Medical?: New Section 301 tariffs of 10 to 12.5 percent on roughly 60 countries took effect July 24, 2026, after the Supreme Court struck down earlier IEEPA-based tariffs in February 2026, directly taxing Chinese-manufactured devices as Mindray expands US operations via its Mahwah, New Jersey warehouse.

Timeline

2026-07-24New Section 301 tariffs of 10 to 12.5 percent take effect on Chinese and other imports to the US
2026-07-15Resona I9T AI-powered ultrasound with AutoEF and eStrain features reviewed
2026-06-02Hepatus 5 and 6 gastroenterology ultrasound and elastography systems launched
2026-03-31FY2025 results reported: revenue down 9.4 percent, domestic China revenue down 23 percent
2026-03-10Resona A20 ultrasound showcased at ECR 2026, placed in UK and Germany hospitals
2026-01-22Mindray unveils three-pillar growth strategy at JPM Healthcare Conference
2025-10-29Q3 2025 revenue rises 1.53 percent year over year to CNY 9.09 billion, signaling stabilization
2025-06-16Mindray North America breaks ground on expanded Mahwah, NJ warehouse
2025-02Former NMPA vice-director detained amid China healthcare anti-corruption campaign
2023-11-30Mindray completes acquisition of 75 percent stake in Germany's DiaSys Diagnostic Systems

Revision history

24 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

DiaSorin S.p.A.Spectris plc Tecan Group